Press Releases
June 2023
06.27.2023
06.26.2023
Research and Pipeline Research Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
06.23.2023
Prescription Medicines Medicines FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
06.22.2023
Financial Finance Pfizer Declares Third-Quarter 2023 Dividend
06.20.2023
Prescription Medicines Medicines Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
06.20.2023
06.06.2023
06.01.2023
May 2023
05.31.2023
05.30.2023
05.25.2023
05.25.2023
Resource Library
Press Kits
These downloadable files, including fact sheets about Pfizer and approved images or videos, are packages curated by the Global Media Relations team for use by professional journalists.
Though intended for professional media, these resources may also be interesting to patients, healthcare professionals, and investors. The media relations team is focused on responding to media inquiries. However, we want to ensure that customers, investors, and others receive the appropriate attention.
For patients or healthcare professionals with questions about Pfizer’s vaccines or medicines, please see our global list of medical information contacts.
For investors with questions about Pfizer’s efforts, please visit our contact page and select "Shareholder Services".
For all other non-media inquiries, please visit the contact us page to reach the appropriate Pfizer contact.
Contact Pfizer Media Relations
Media Contacts
United States, Canada, and Latin America
+1 212.733.1226
Europe, Middle East, and Africa
+44-(0)845.300.8033
Asia Pacific
+65.918.732.47
Email
[email protected]